Bannier A, Comet F, Soubeyrand J, Brazier J L, Chauliac F
Eur J Clin Pharmacol. 1985;28(4):433-7. doi: 10.1007/BF00544363.
The interaction between isofezolac and probenecid has been studied with the aid of a specific HPLC assay for isofezolac in plasma and urine. 8 healthy adult volunteers received a single 40 mg oral dose of isofezolac before and after 3 days of loading with 0.5 probenecid t.i.d. There was an increase in the maximum plasma isofezolac concentration from 2.44 to 3.38 micrograms X ml-1 when probenecid was given. The AUC of isofezolac in plasma increased from 6.73 to 11.28 micrograms X h X ml-1. After the last dose in a 7 day treatment with 40 mg isofezolac t.i.d., there was an increase in the maximum plasma isofezolac level from 2.84 to 4.96 micrograms X ml-1 when probenecid was given. The rate of absorption of isofezolac was not affected. An increase in the AUC of isofezolac in plasma was observed from 11.74 to 26.34 micrograms X h X ml-1. The major effect of probenecid on isofezolac metabolism was a 50% reduction in total isofezolac (free + conjugates) excreted inurine. Because of this interaction, patients given isofezolac combined with probenecid will have a higher steady-state plasma level of isofezolac than when probenecid is not administered.
借助一种针对血浆和尿液中异氟扎酯的特定高效液相色谱分析法,对异氟扎酯与丙磺舒之间的相互作用进行了研究。8名健康成年志愿者在连续3天每日3次服用0.5克丙磺舒进行负荷给药前后,分别单次口服40毫克异氟扎酯。服用丙磺舒后,血浆中异氟扎酯的最大浓度从2.44微克/毫升增至3.38微克/毫升。异氟扎酯在血浆中的药时曲线下面积从6.73微克·小时/毫升增至11.28微克·小时/毫升。在用异氟扎酯每日3次、每次40毫克进行为期7天的治疗后,最后一剂给药后,服用丙磺舒时血浆中异氟扎酯的最大水平从2.84微克/毫升增至4.96微克/毫升。异氟扎酯的吸收速率未受影响。观察到异氟扎酯在血浆中的药时曲线下面积从11.74微克·小时/毫升增至26.34微克·小时/毫升。丙磺舒对异氟扎酯代谢的主要影响是使尿液中排泄的总异氟扎酯(游离型+结合型)减少50%。由于这种相互作用,服用异氟扎酯与丙磺舒联合制剂的患者,其异氟扎酯的稳态血浆水平将高于未服用丙磺舒时的水平。